Design, Synthesis, Bio-evaluation, and Studies of Some N-substituted 6-(chloro/nitro)-1-benzimidazole Derivatives As Antimicrobial and Anticancer Agents
Overview
Affiliations
A new series of 6-substituted 1-benzimidazole derivatives were synthesized by reacting various substituted aromatic aldehydes with 4-nitro--phenylenediamine and 4-chloro--phenylenediamine through condensation using sodium metabisulfite as the oxidative reagent. The N-substituted 6-(chloro/nitro)-1-benzimidazole derivatives were prepared from the 6-substituted 1-benzimidazole derivatives and substituted halides using potassium carbonate by conventional methods as well as by exposure to microwave irradiation. Seventy-six 1-benzimidazole derivatives have been synthesized in moderate to excellent yields with the microwave-assisted method (40 to 99%). Compounds 1d, 2d, 3s, 4b, and 4k showed potent antibacterial activity against , , MSSA (methicillin-susceptible strains of ), and MRSA (methicillin-resistant strains of ) with MIC (the minimum inhibitory concentration) ranging between 2 and 16 μg mL as compared to ciprofloxacin (MIC = 8-16 μg mL), in particular compound 4k exhibits potent fungal activity against and with MIC ranging between 8 and 16 μg mL compared with the standard drug fluconazole (MIC = 4-128 μg mL). In addition, compounds 1d, 2d, 3s, 4b, and 4k also showed the strongest anticancer activity among the synthesized compounds against five tested cell lines with IC (half-maximal inhibitory concentration) ranging between 1.84 and 10.28 μg mL, comparable to paclitaxel (IC = 1.38-6.13 μM). Furthermore, the five most active compounds showed a good ADMET (absorption, distribution, metabolism, excretion, and toxicity) profile in comparison to ciprofloxacin, fluconazole, and paclitaxel as reference drugs. Molecular docking predicted that dihydrofolate reductase protein from is the most suitable target for both antimicrobial and anticancer activities, and vascular endothelial growth factor receptor 2 and histone deacetylase 6 are the most suitable targets for anticancer activity of these potent compounds.
Dastyafteh N, Negahdaripour M, Sayahi M, Emami M, Ghasemi Y, Safaei E RSC Adv. 2024; 14(48):35323-35335.
PMID: 39502175 PMC: 11536976. DOI: 10.1039/d4ra04492d.
and antihypertensive, anti-inflammatory, and analgesic activities of Del. leaf extracts.
Pham E, Van Doan V, Le Thi T, Van Ngo C, Vo Van L Heliyon. 2024; 10(19):e38634.
PMID: 39435095 PMC: 11492254. DOI: 10.1016/j.heliyon.2024.e38634.
Phan N, Huynh T, Nguyen H, Le Q, Nguyen T, Ngo K ACS Omega. 2023; 8(31):28733-28748.
PMID: 37576624 PMC: 10413844. DOI: 10.1021/acsomega.3c03530.
Pham E, Le Thi T, Ly Hong H, Vo Thi B, Vong L, Vu T RSC Adv. 2023; 13(1):399-420.
PMID: 36605630 PMC: 9782508. DOI: 10.1039/d2ra06667j.
Pham E, Truong T ACS Omega. 2022; 7(37):33614-33628.
PMID: 36157776 PMC: 9494668. DOI: 10.1021/acsomega.2c05206.